Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
US10238659B2 · kind B2 · utility
10Cited by
2References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 14, 2015 |
| Grant date | Mar 26, 2019 |
| Priority date | — |
| Expiry date | Oct 14, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.